Loading…
← CockpitCompetitor Analysis › POLYMED.NS Poly MedicureOpen in the cockpit ↗

Poly MedicurePOLYMED.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Medical Specialties

Indian manufacturer of medical devices such as IV cannulas, infusion sets and other disposables, with significant export sales.

≈ India's smaller Becton Dickinson for disposable medical devicesMomentum strong 62
Mkt cap
$1.79B
US dollars, full cap
Free float
31%
of shares outstanding
$/day
$1.33M
20-day average traded
Fwd P/E
39.9×
forward earnings
ROIC−WACC
-4.8 pp
WACC 13.6%
Hurdle
n/a
no reverse DCF
Next earnings
65 days
22 Jan 2027
Close · INR₹1,654
1D+0.3%
1W-1.1%
1M+6.7%
3M-7.3%
6M+13.7%
YTD-6.7%
1Y-18.3%
ATR %3.3%
Beta0.85
52w lowhigh18.3% off high

What Poly Medicure does

Indian manufacturer of medical devices such as IV cannulas, infusion sets and other disposables, with significant export sales.

Sells high-volume disposable devices to hospitals through distributors at home and through importers abroad, and exports are a large share of sales. Hospitals use the items once and reorder, so volumes repeat. Founder Himanshu Baid leads the company.

In one line: India's smaller Becton Dickinson for disposable medical devices.

Products and services

  • IV cannulas
  • Infusion/transfusion sets
  • Surgical/urology disposables

Customers

  • Hospitals globally (export-heavy)
  • Healthcare distributors

Where it sits in the supply chain

  • Healthcare/medical devices
  • Medical device manufacturing
  • IV therapy & disposable devices

What could go right

  • Global demand for low-cost disposable medical devices
  • Import substitution/China+1 sourcing shift

What could go wrong

  • Pricing pressure from global tenders
  • Regulatory compliance costs (FDA/CE)

Moat: narrow (scale, regulatory licence, cost advantage). Large-scale, cost-competitive manufacturing with regulatory approvals (CE, US FDA) enabling global exports.

Headquarters: Faridabad, India · Founded: 1995 · Employees: 2,614

Named competitors

Poly Medicure at a glance

Size Poly Medicure (POLYMED.NS) is an India Health Care company (Medical Specialties) with a market value of $1.79B, the 411th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,654 on 18 Nov 2026.

Performance Over six months the shares gained 13.7%, against +1.5% for the median peer and +3.8% for the India market (cap-weighted) — 7th highest of 20 in its peer set.

Growth Revenue grew 24.6% over the last twelve months (peer median +9.6%); the operating margin is 16.2% (peer median 12.7%).

Valuation It trades at 39.9× forward earnings against a peer median of 25.1× (6th most expensive of 18).

Capital Return on invested capital runs 4.8 points below its cost of capital (13.6% WACC).

Next results Next results expected around 22 Jan 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026POLYMED.NS 113Peer median 99
Six months, rebased to 100: Poly Medicure against the median of its 20 peers (local-currency closes).

Poly Medicure financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹21.3B₹18.6B₹16.6B₹13.7B₹11.1B
Revenue growth—+12%+21%+23%—
Gross profit₹8.50B₹5.36B₹5.10B₹4.07B₹3.00B
EBITDA₹4.84B₹4.52B₹4.52B₹3.61B₹2.71B
Net income₹3.18B₹3.22B₹3.39B₹2.58B₹1.79B
Free cash flown/a-₹602M-₹941M-₹82.4M-₹546M
Capital expendituren/a₹3.08B₹3.31B₹2.77B₹2.39B
Total debt₹4.12B₹3.54B₹1.80B₹1.74B₹1.49B

Quarterly statements and history in the cockpit →

Poly Medicure competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%7716CHEMM10666960268ASKANMEDLMAT301363EMBLAKMTSINSP8086BFLY301087688531VITRPOLYMED.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Poly Medicure is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%20×40×60×7716CHEMM10666960268ASKANMED301363EMBLAXRAYINSP6699301087688531VITRPOLYMED.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Poly Medicure is the large dot.

Poly Medicure competitors and peer comparison

Head to head with its named competitors (POLYMED.NS vs BDX)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Poly Medicure POLYMED.NS$1.79B+14%+25%16%39.9×n/a
Becton Dickinson BDX$58.9B+48%-7%16%16.3×-1.6%

How Poly Medicure compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Poly Medicure against its 20 peers (data as of 18 Nov 2026)
MeasurePOLYMED.NSPeer medianRank in peer set
1-month return+6.7%-5.0%5th highest of 21
6-month return+13.7%+1.5%7th highest of 20
Distance from 52-week high-18.3%-24.8%9th highest of 21
Revenue growth (TTM)+24.6%+9.6%8th highest of 21
Operating margin16.2%12.7%9th highest of 21
Forward P/E39.9×25.1×6th most expensive of 18
ROIC minus cost of capital-4.8 pp+0.6 pp7th lowest of 21
EV / EBITDA33.8×15.7×4th most expensive of 15
Net debt / EBITDA-0.8×-0.7×7th least indebted of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Poly Medicure POLYMED.NSIndia$1.79B+14%+25%16%39.9×n/an/a
Nakanishi 7716.TJapan$1.78B+7%+17%21%19.0×4.8%+19.7%
ChemoMetec A/S CHEMM.CODenmark$1.77B+107%+3%49%46.7×19.4%+12.7%
Shandong Weigao Group Medical Polymer 1066.HKHong Kong$1.82B-8%+7%14%8.2×-12.6%+2.1%
Fukuda Denshi 6960.TJapan$1.84B+4%0%19%15.4×-1.6%-1.0%
Rigaku 268A.TJapan$1.85B-54%+9%16%23.1×18.3%+14.5%
Molbio Diagnostics MOLBIO.NSIndia$1.85Bn/a+35%17%n/an/an/a
SKAN SKAN.SWSwitzerland$1.85B+40%+9%11%49.5×13.8%+11.7%
Medartis MED.SWSwitzerland$1.86B+47%+30%2%72.8×n/an/a
LeMaitre Vascular LMATUnited States$1.73B-25%+12%28%24.5×2.9%+14.0%
Mehow Innovative 301363.SZChina$1.72B-36%+10%21%34.2×16.4%+12.9%
Embla Medical hf EMBLA.CODenmark$1.72B+1%+6%14%17.2×-1.9%+8.3%
DENTSPLY SIRONA XRAYUnited States$1.69B-13%-1%5%6.8×11.2%+1.9%
Kestra Medical Technologies KMTSUnited States$1.69B+36%+61%-134%n/an/an/a
Inspire Medical Systems INSPUnited States$1.68B+32%0%2%41.3×28.7%+51.2%
NIPRO 8086.TJapan$1.68B-11%+5%5%15.8×n/an/a
Butterfly Network BFLYUnited States$1.63B+38%+39%-36%n/an/an/a
Angelalign Technology 6699.HKHong Kong$1.62B-8%+84%9%52.5×16.7%+25.8%
Cofoe Medical Technology 301087.SZChina$1.60B-6%+33%10%25.1×11.2%+7.4%
Wuxi Unicomp Technology 688531.SSChina$1.58B-49%+53%12%35.8×n/an/a
Vitrolife VITR.STSweden$1.57B+13%-2%19%27.0×22.2%+22.5%

Questions

Who are Poly Medicure's main competitors?
Named competitors: Becton Dickinson (BDX). The cockpit's measured peer set (industry) also includes Nakanishi (7716.T), ChemoMetec A/S (CHEMM.CO), Shandong Weigao Group Medical Polymer (1066.HK), Fukuda Denshi (6960.T), Rigaku (268A.T), Molbio Diagnostics (MOLBIO.NS).
Is Poly Medicure expensive compared with its peers?
On forward p/e it trades at 39.9× against a peer median of 25.1×, 6th most expensive of 18 in its peer set.
How has Poly Medicure stock performed?
Over six months to 18 Nov 2026 the shares returned +13.7% against +1.5% for the median peer; over one year -18.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.